​

Castle Biosciences (CSTL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CSTL Stock Forecast

Castle Biosciences (CSTL) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $38.00, with a high of $45.00 and a low of $30.00. This represents a 78.74% increase from the last price of $21.26.

$15 $21 $27 $33 $39 $45 High: $45 Avg: $38 Low: $30 Last Closed Price: $21.26

CSTL Stock Rating

Castle Biosciences stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 9 Strong Sell Sell Hold Buy Strong Buy

CSTL Price Target Upside V Benchmarks

TypeNameUpside
StockCastle Biosciences78.74%
SectorHealthcare Stocks 33.91%
IndustryDiagnostics & Research Stocks45.48%

Price Target Trends

1M3M12M
# Anlaysts128
Avg Price Target$30.00$33.50$38.00
Last Closing Price$21.26$21.26$21.26
Upside/Downside41.11%57.57%78.74%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2518---9
Mar, 2518---9
Feb, 2518---9
Jan, 2518---9
Dec, 2418---9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 28, 2025Subbu NambiGuggenheim$30.00$20.1049.25%41.11%
Feb 28, 2025Robert W. Baird$37.00$21.6870.66%74.04%
Nov 05, 2024Sung Ji NamBTIG$45.00$31.1544.46%111.67%
Nov 05, 2024Catherine SchulteRobert W. Baird$39.00$32.8018.90%83.44%
Nov 05, 2024Paul KnightKeyBanc$36.00$32.809.76%69.33%
Oct 29, 2024Kyle MiksonCanaccord Genuity$42.00$32.4029.63%97.55%
Oct 14, 2024Sung Ji NamBTIG$40.00$31.3127.75%88.15%
Aug 06, 2024Sung Ji NamBTIG$35.00$26.2433.38%64.63%
Nov 04, 2022Catherine Schulte AnalystRobert W. Baird$41.00$24.7265.86%92.85%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 28, 2025GuggenheimBuyBuyhold
Nov 05, 2024KeyBancOverweightOverweighthold
Oct 29, 2024StephensBuyBuyhold
Oct 29, 2024Canaccord GenuityBuyBuyhold
Oct 14, 2024BTIGBuyBuyhold
Aug 06, 2024BTIGBuyBuyhold
May 03, 2024Lake StreetBuyBuyhold
Jun 15, 2023BTIGBuyBuyhold
Jun 06, 2023Canaccord GenuityBuyBuyhold
Jan 05, 2023ScotiabankSector Outperforminitialise

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.54$-1.24$-2.58$-2.14$0.66----
Avg Forecast$-0.41$-1.46$-2.72$-2.60$0.39$-1.79$-1.38$-1.22$-0.18
High Forecast$-0.39$-1.40$-2.65$-2.34$0.42$-1.22$-0.40$-0.28$-0.17
Low Forecast$-0.42$-1.51$-2.84$-2.86$0.35$-2.35$-2.54$-2.29$-0.19
Surprise %31.71%-15.07%-5.15%-17.69%69.23%----

Revenue Forecast

$50M $120M $190M $260M $330M $400M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$62.65M$94.08M$137.04M$219.79M$332.07M----
Avg Forecast$61.11M$92.78M$135.89M$209.95M$327.49M$274.08M$304.02M$325.14M$367.70M
High Forecast$62.73M$95.23M$140.49M$215.07M$345.82M$289.42M$309.11M$325.14M$388.28M
Low Forecast$59.36M$90.12M$132.96M$204.83M$318.47M$266.53M$298.94M$325.14M$357.57M
Surprise %2.52%1.41%0.84%4.69%1.40%----

Net Income Forecast

$-70M $-52M $-34M $-16M $2M $20M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-10.28M$-31.29M$-67.14M$-57.47M$18.25M----
Avg Forecast$-10.87M$-30.90M$-45.27M$-57.47M$10.37M$-50.49M$-35.73M$-21.80M$-4.69M
High Forecast$-10.47M$-24.72M$-36.21M$-45.97M$11.31M$-32.66M$-10.78M$-7.50M$-4.52M
Low Forecast$-11.25M$-37.07M$-54.32M$-68.96M$9.42M$-63.08M$-68.20M$-61.38M$-5.03M
Surprise %-5.41%1.28%48.31%-75.98%----

CSTL Forecast FAQ

Is Castle Biosciences stock a buy?

Castle Biosciences stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Castle Biosciences is a favorable investment for most analysts.

What is Castle Biosciences's price target?

Castle Biosciences's price target, set by 9 Wall Street analysts, averages $38 over the next 12 months. The price target range spans from $30 at the low end to $45 at the high end, suggesting a potential 78.74% change from the previous closing price of $21.26.

How does Castle Biosciences stock forecast compare to its benchmarks?

Castle Biosciences's stock forecast shows a 78.74% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the diagnostics & research stocks industry (45.48%).

What is the breakdown of analyst ratings for Castle Biosciences over the past three months?

  • April 2025: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Castle Biosciences’s EPS forecast?

Castle Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.79, marking a -371.21% decrease from the reported $0.66 in 2024. Estimates for the following years are $-1.38 in 2026, $-1.22 in 2027, and $-0.18 in 2028.

What is Castle Biosciences’s revenue forecast?

Castle Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $274.08M, reflecting a -17.46% decrease from the reported $332.07M in 2024. The forecast for 2026 is $304.02M, followed by $325.14M for 2027, and $367.7M for 2028.

What is Castle Biosciences’s net income forecast?

Castle Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $-50.486M, representing a -376.71% decrease from the reported $18.24M in 2024. Projections indicate $-35.725M in 2026, $-21.8M in 2027, and $-4.69M in 2028.